Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams
Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)
DOI: 10.1128/aac.01910-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Ava J Dorazio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Pseudomonas aeruginosa, Ceftazidime, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Twelve pairs of baseline and post-exposure Pseudomonas aeruginosa isolates from patients treated with ceftazidime-avibactam were evaluated to define mechanisms of treatment-emergent resistance. Resistance was associated with amino acid substitutions in ampC and OXA β-lactamases, or mutations in regulatory genes conferring hyper-production of AmpC and MexAB-OprM efflux pumps. Cross-resistance was common between ceftazidime-avibactam and ceftolozane-tazobactam, less common for imipenem-relebactam and cefepime-zidebactam, and lowest for cefiderocol. These findings have important implications for sequential treatment of P. aeruginosa infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Center for Innovative Antimicrobial Therapy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Center for Evolutionary Biology and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
- College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Ava J Dorazio, Ellen G Kline, Daria Van Tyne, Jason M Pogue, Ryan K Shields
Zitieren
APA
Dorazio, A. J., Kline, E. G., Squires, K. M., Shah, S., Van Tyne, D., Wu, J. Y., Pogue, J. M., & Shields, R. K. (2026). Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01910-25
Vancouver
Dorazio AJ, Kline EG, Squires KM, Shah S, Van Tyne D, Wu JY, et al. Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01910-25
BibTeX
@article{Dorazio2026,
author = {Dorazio, Ava J and Kline, Ellen G and Squires, Kevin M and Shah, Sunish and Van Tyne, Daria and Wu, Janet Y and Pogue, Jason M and Shields, Ryan K},
title = {Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {5},
doi = {10.1128/aac.01910-25}
}
EUVIMED